|
Sign In to gain access to subscriptions and/or personal tools.
|
Laboratory diagnosis and management challenges in the antiphospholipid syndrome
M L Bertolaccini
Lupus Research Unit, The Rayne Institute, Kings College London School of Medicine at Guys, Kings and St Thomas Hospitals, St Thomas Hospital, London, UK, maria.bertolaccini{at}kcl.ac.uk
M A Khamashta
Lupus Research Unit, The Rayne Institute, Kings College London School of Medicine at Guys, Kings and St Thomas Hospitals, St Thomas Hospital, London, UK
The antiphospholipid syndrome (APS) is characterized by recurrent arterial and/or venous thrombosis and pregnancy morbidity manifested by early or late losses. Laboratory diagnosis of APS relies on the demonstration of a positive test for antiphospholipid antibodies (aPL). In clinical practice, the gold standard tests are those that detect anticardiolipin antibodies (aCL) and/or the lupus anticoagulant (LA). Although other specificities for aPL have been described their clinical utility and standardization has still to be established. Persistence of aPL positive tests must be demonstrated, and other causes and underlying factors considered. Although it is universally recognized that the routine screening tests (aCL and/or LA) might miss some cases, careful differential diagnosis and repeat testing are mandatory before the diagnosis of seronegative APS can be made. Correct identification of patients with APS is important, because prophylactic anticoagulant therapy can prevent thrombosis from recurring, and treatment of affected women during pregnancy can improve fetal and maternal outcome.
Key Words: anticardiolipin heparin lupus anticoagulant pregnancy morbidity thrombosis warfarin
Lupus, Vol. 15, No. 3,
172-178 (2006)
DOI: 10.1191/0961203306lu2293rr

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati Twitter What's this?
This article has been cited by other articles:

|
 |

|
 |
 
Y.-H. Yang, C.-J. Chang, Y.-H. Chuang, H.-Y. Hsu, P. P. Chen, and B.-L. Chiang
Identification of anti-prothrombin antibodies in the anti-phospholipid syndrome that display the prothrombinase activity
Rheumatology,
November 17, 2009;
(2009)
kep328v1.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y.-H. Yang, D. Chien, M. Wu, J. FitzGerald, J. M. Grossman, B. H. Hahn, K.-K. Hwang, and P. P. Chen
Novel Autoantibodies against the Activated Coagulation Factor IX (FIXa) in the Antiphospholipid Syndrome That Interpose the FIXa Regulation by Antithrombin
J. Immunol.,
February 1, 2009;
182(3):
1674 - 1680.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Wu, D. J. Birmingham, B. Rovin, K. V. Hackshaw, N. Haddad, D. Haden, C.-Y. Yu, and L. A. Hebert
D-Dimer Level and the Risk for Thrombosis in Systemic Lupus Erythematosus
Clin. J. Am. Soc. Nephrol.,
November 1, 2008;
3(6):
1628 - 1636.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Gorki, V. Malinovski, and R. D.L. Stanbridge
The antiphospholipid syndrome and heart valve surgery
Eur. J. Cardiothorac. Surg.,
February 1, 2008;
33(2):
168 - 181.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. J. Swigris, A. Fischer, J. Gilles, R. T. Meehan, and K. K. Brown
Pulmonary and Thrombotic Manifestations of Systemic Lupus Erythematosus
Chest,
January 1, 2008;
133(1):
271 - 280.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Metzger, P. von Landenberg, M. Kehrel, A. Buhl, K. J. Lackner, and P. B. Luppa
Biosensor Analysis of {beta}2-Glycoprotein I-Reactive Autoantibodies: Evidence for Isotype-Specific Binding and Differentiation of Pathogenic from Infection-Induced Antibodies
Clin. Chem.,
June 1, 2007;
53(6):
1137 - 1143.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. F. Smith Jr and M. L. Druzin
Perinatal Implications of the Antiphospholipid Syndrome
NeoReviews,
May 1, 2007;
8(5):
e206 - e213.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F Cacciapaglia, M Vadacca, G Coppolino, F Buzzulini, A Rigon, D Zennaro, E Zardi, and A Afeltra
Spontaneous splenorenal shunt in a patient with antiphospholipid syndrome: the first case reported
Lupus,
January 1, 2007;
16(1):
56 - 58.
[Abstract]
[PDF]
|
 |
|
|
|